|
|
|
| home > epc > autumn 2002 > a different strategy in a changing world of infectious substances |
|
|
 PUBLICATIONS |
European Pharmaceutical Contractor
|
On the 5th July 2002 UN scrutinisers voted unanimously passing far-reaching legislation for the next edition (13th revised edition) on infectious substances. It is quite remarkable, considering that only a year ago it would have taken a days spirited debate just to change a few words in the existing text. Was there a momentous sea-change by experts on their views of dangerous bugs? Or did other influences come to bear? Think back to the autumn of 2001.
The deliberate release of biological agents through the mail system in the United States completely changed the focus on hazardous materials. 'Hazmat' bioterror swiftly shot up the political and scientific agenda. Many governments, particularly in North America and Europe, took measures to increase preparedness and response capacity. Therefore, not surprisingly, transport officials needed to open a dialogue with the scientific community and start to understand the rationales which underpin the infectious substance class. This UN meeting was the culmination of a year's solid work for regulators and scientists. Many observers agree that the impending '13th revised edition' is unequivocally a positive regulatory milestone. Now it remains to be seen how the world will progress in the intervening years until it is published in 2004.
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
BioPartnering North America™
26-28 February 2012, Vancouver Convention Centre, Vancouver, BC, Canada
BioPartnering North America 2012 (BPN) in Vancouver, Canada brings together senior executives from venture capital firms, major pharmaceutical companies, academic institutions and biotechnology companies of every size from mature to start-up.
More info >> |
|
 |
News and Press Releases |
 |
Norwich Expands Capabilities for Phase I-III Clinical Trials
Norwich Clinical Services (NCS), a global provider of clinical research services for the pharmaceutical and biotech industries, today announced a significant expansion to its clinical research capabilities in order to meet growing market demand. Primary to the expansion, NCS unveiled a new clinical facility with capabilities to conduct all aspects of Phase I – III clinical trials including pharmacokinetics in healthy volunteers, bio-availability and bio-equivalence studies, drug metabolism studies, dose proportionality studies and multiple dose studies.
More info >> |
|
|
